Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the national Wilms tumor study group

Marcio Malogolowkin, Cecilia A. Cotton, Daniel M. Green, Norman E. Breslow, Elizabeth Perlman, James Miser, Michael L. Ritchey, Patrick R.M. Thomas, Paul E. Grundy, Giulio J. D'Angio, J. Bruce Beckwith, Robert C. Shamberger, Gerald M. Haase, Milton Donaldson, Robert Weetman, Max J. Coppes, Patricia Shearer, Peter Coccia, Morris Kletzel, Roger MacklisGail Tomlinson, Vicki Huff, Robert Newbury, Douglas Weeks

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objective. We evaluated the use of alternating cycles of cyclophosphamide/etoposide and carboplatin/etoposide in children entered on National Wilms Tumor Study (NWTS)-5 who were diagnosed between August 1, 1995 and May 31, 2002 and who relapsed after chemotherapy with vincristine, actinomycin D, and doxorubicin (VAD) and radiation therapy (DD-4A). Patients And Methods. One hundred three patients who relapsed or had progressive disease after initial VAD chemotherapy and radiation therapy were registered on stratum C of the NWTS-5 Relapse protocol. Twelve patients were not evaluable: five due to insufficient data, six due to major protocol violations, and one for refusal of therapy. Among the 91 remaining patients, 14 with stage V Wilms tumor (WT), 1 with contralateral relapse, and 16 who did not achieve a complete response (CR) to the initial three-drug chemotherapy were not included in this analysis. Relapse treatment included alternating courses of the drug pairs cyclophosphamide/etoposide and carboplatin/etoposide, surgery, and radiation therapy. Results. The outcomes of 60 patients were analyzed. The lung was the only site of relapse for 33 patients; other sites of relapse included the operative bed, the abdomen, and liver. Four-year event-free survival (EFS) and overall survival (OS) were 42.3 and 48.0% respectively for all patients and were 48.9 and 52.8% for those who relapsed in the lungs only. Thrombocytopenia was the most frequent toxicity. Conclusion. These results demonstrate that approximately one-half of children with unilateral WT who relapse after initial treatment with VAD and radiation therapy can be successfully retreated.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalPediatric Blood and Cancer
Volume50
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Wilms Tumor
Dactinomycin
Vincristine
Doxorubicin
Etoposide
Recurrence
Radiotherapy
Carboplatin
Drug Therapy
Cyclophosphamide
Therapeutics
Lung
Thrombocytopenia
Pharmaceutical Preparations
Abdomen
Disease-Free Survival
Survival
Liver

Keywords

  • Chemotherapy
  • Phase II clinical trials
  • Radiation oncology
  • Solid tumors
  • Wilms tumor (WT)

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the national Wilms tumor study group. / Malogolowkin, Marcio; Cotton, Cecilia A.; Green, Daniel M.; Breslow, Norman E.; Perlman, Elizabeth; Miser, James; Ritchey, Michael L.; Thomas, Patrick R.M.; Grundy, Paul E.; D'Angio, Giulio J.; Beckwith, J. Bruce; Shamberger, Robert C.; Haase, Gerald M.; Donaldson, Milton; Weetman, Robert; Coppes, Max J.; Shearer, Patricia; Coccia, Peter; Kletzel, Morris; Macklis, Roger; Tomlinson, Gail; Huff, Vicki; Newbury, Robert; Weeks, Douglas.

In: Pediatric Blood and Cancer, Vol. 50, No. 2, 01.02.2008, p. 236-241.

Research output: Contribution to journalArticle

Malogolowkin, M, Cotton, CA, Green, DM, Breslow, NE, Perlman, E, Miser, J, Ritchey, ML, Thomas, PRM, Grundy, PE, D'Angio, GJ, Beckwith, JB, Shamberger, RC, Haase, GM, Donaldson, M, Weetman, R, Coppes, MJ, Shearer, P, Coccia, P, Kletzel, M, Macklis, R, Tomlinson, G, Huff, V, Newbury, R & Weeks, D 2008, 'Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the national Wilms tumor study group', Pediatric Blood and Cancer, vol. 50, no. 2, pp. 236-241. https://doi.org/10.1002/pbc.21267
Malogolowkin, Marcio ; Cotton, Cecilia A. ; Green, Daniel M. ; Breslow, Norman E. ; Perlman, Elizabeth ; Miser, James ; Ritchey, Michael L. ; Thomas, Patrick R.M. ; Grundy, Paul E. ; D'Angio, Giulio J. ; Beckwith, J. Bruce ; Shamberger, Robert C. ; Haase, Gerald M. ; Donaldson, Milton ; Weetman, Robert ; Coppes, Max J. ; Shearer, Patricia ; Coccia, Peter ; Kletzel, Morris ; Macklis, Roger ; Tomlinson, Gail ; Huff, Vicki ; Newbury, Robert ; Weeks, Douglas. / Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the national Wilms tumor study group. In: Pediatric Blood and Cancer. 2008 ; Vol. 50, No. 2. pp. 236-241.
@article{cf66cab4a18e4ddab2f1bf0c25c62d4f,
title = "Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the national Wilms tumor study group",
abstract = "Objective. We evaluated the use of alternating cycles of cyclophosphamide/etoposide and carboplatin/etoposide in children entered on National Wilms Tumor Study (NWTS)-5 who were diagnosed between August 1, 1995 and May 31, 2002 and who relapsed after chemotherapy with vincristine, actinomycin D, and doxorubicin (VAD) and radiation therapy (DD-4A). Patients And Methods. One hundred three patients who relapsed or had progressive disease after initial VAD chemotherapy and radiation therapy were registered on stratum C of the NWTS-5 Relapse protocol. Twelve patients were not evaluable: five due to insufficient data, six due to major protocol violations, and one for refusal of therapy. Among the 91 remaining patients, 14 with stage V Wilms tumor (WT), 1 with contralateral relapse, and 16 who did not achieve a complete response (CR) to the initial three-drug chemotherapy were not included in this analysis. Relapse treatment included alternating courses of the drug pairs cyclophosphamide/etoposide and carboplatin/etoposide, surgery, and radiation therapy. Results. The outcomes of 60 patients were analyzed. The lung was the only site of relapse for 33 patients; other sites of relapse included the operative bed, the abdomen, and liver. Four-year event-free survival (EFS) and overall survival (OS) were 42.3 and 48.0{\%} respectively for all patients and were 48.9 and 52.8{\%} for those who relapsed in the lungs only. Thrombocytopenia was the most frequent toxicity. Conclusion. These results demonstrate that approximately one-half of children with unilateral WT who relapse after initial treatment with VAD and radiation therapy can be successfully retreated.",
keywords = "Chemotherapy, Phase II clinical trials, Radiation oncology, Solid tumors, Wilms tumor (WT)",
author = "Marcio Malogolowkin and Cotton, {Cecilia A.} and Green, {Daniel M.} and Breslow, {Norman E.} and Elizabeth Perlman and James Miser and Ritchey, {Michael L.} and Thomas, {Patrick R.M.} and Grundy, {Paul E.} and D'Angio, {Giulio J.} and Beckwith, {J. Bruce} and Shamberger, {Robert C.} and Haase, {Gerald M.} and Milton Donaldson and Robert Weetman and Coppes, {Max J.} and Patricia Shearer and Peter Coccia and Morris Kletzel and Roger Macklis and Gail Tomlinson and Vicki Huff and Robert Newbury and Douglas Weeks",
year = "2008",
month = "2",
day = "1",
doi = "10.1002/pbc.21267",
language = "English (US)",
volume = "50",
pages = "236--241",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the national Wilms tumor study group

AU - Malogolowkin, Marcio

AU - Cotton, Cecilia A.

AU - Green, Daniel M.

AU - Breslow, Norman E.

AU - Perlman, Elizabeth

AU - Miser, James

AU - Ritchey, Michael L.

AU - Thomas, Patrick R.M.

AU - Grundy, Paul E.

AU - D'Angio, Giulio J.

AU - Beckwith, J. Bruce

AU - Shamberger, Robert C.

AU - Haase, Gerald M.

AU - Donaldson, Milton

AU - Weetman, Robert

AU - Coppes, Max J.

AU - Shearer, Patricia

AU - Coccia, Peter

AU - Kletzel, Morris

AU - Macklis, Roger

AU - Tomlinson, Gail

AU - Huff, Vicki

AU - Newbury, Robert

AU - Weeks, Douglas

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Objective. We evaluated the use of alternating cycles of cyclophosphamide/etoposide and carboplatin/etoposide in children entered on National Wilms Tumor Study (NWTS)-5 who were diagnosed between August 1, 1995 and May 31, 2002 and who relapsed after chemotherapy with vincristine, actinomycin D, and doxorubicin (VAD) and radiation therapy (DD-4A). Patients And Methods. One hundred three patients who relapsed or had progressive disease after initial VAD chemotherapy and radiation therapy were registered on stratum C of the NWTS-5 Relapse protocol. Twelve patients were not evaluable: five due to insufficient data, six due to major protocol violations, and one for refusal of therapy. Among the 91 remaining patients, 14 with stage V Wilms tumor (WT), 1 with contralateral relapse, and 16 who did not achieve a complete response (CR) to the initial three-drug chemotherapy were not included in this analysis. Relapse treatment included alternating courses of the drug pairs cyclophosphamide/etoposide and carboplatin/etoposide, surgery, and radiation therapy. Results. The outcomes of 60 patients were analyzed. The lung was the only site of relapse for 33 patients; other sites of relapse included the operative bed, the abdomen, and liver. Four-year event-free survival (EFS) and overall survival (OS) were 42.3 and 48.0% respectively for all patients and were 48.9 and 52.8% for those who relapsed in the lungs only. Thrombocytopenia was the most frequent toxicity. Conclusion. These results demonstrate that approximately one-half of children with unilateral WT who relapse after initial treatment with VAD and radiation therapy can be successfully retreated.

AB - Objective. We evaluated the use of alternating cycles of cyclophosphamide/etoposide and carboplatin/etoposide in children entered on National Wilms Tumor Study (NWTS)-5 who were diagnosed between August 1, 1995 and May 31, 2002 and who relapsed after chemotherapy with vincristine, actinomycin D, and doxorubicin (VAD) and radiation therapy (DD-4A). Patients And Methods. One hundred three patients who relapsed or had progressive disease after initial VAD chemotherapy and radiation therapy were registered on stratum C of the NWTS-5 Relapse protocol. Twelve patients were not evaluable: five due to insufficient data, six due to major protocol violations, and one for refusal of therapy. Among the 91 remaining patients, 14 with stage V Wilms tumor (WT), 1 with contralateral relapse, and 16 who did not achieve a complete response (CR) to the initial three-drug chemotherapy were not included in this analysis. Relapse treatment included alternating courses of the drug pairs cyclophosphamide/etoposide and carboplatin/etoposide, surgery, and radiation therapy. Results. The outcomes of 60 patients were analyzed. The lung was the only site of relapse for 33 patients; other sites of relapse included the operative bed, the abdomen, and liver. Four-year event-free survival (EFS) and overall survival (OS) were 42.3 and 48.0% respectively for all patients and were 48.9 and 52.8% for those who relapsed in the lungs only. Thrombocytopenia was the most frequent toxicity. Conclusion. These results demonstrate that approximately one-half of children with unilateral WT who relapse after initial treatment with VAD and radiation therapy can be successfully retreated.

KW - Chemotherapy

KW - Phase II clinical trials

KW - Radiation oncology

KW - Solid tumors

KW - Wilms tumor (WT)

UR - http://www.scopus.com/inward/record.url?scp=37549055839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549055839&partnerID=8YFLogxK

U2 - 10.1002/pbc.21267

DO - 10.1002/pbc.21267

M3 - Article

C2 - 17539021

AN - SCOPUS:37549055839

VL - 50

SP - 236

EP - 241

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -